CY-09

SKU: orb1303099

Description

CY-09

Research Area

Immunology & Inflammation, Signal Transduction

Key Properties

• CAS Number: 1073612-91-5
• MW: 423.43
• Purity: 99.25%
• Formula: C₁₉H₁₂F₃NO₃S₂
• SMILES: OC(=O)c1ccc(C=C2SC(=S)N(Cc3cccc(c3)C(F)(F)F)C2=O)cc1
• Target: NOD,NOD-like Receptor (NLR)
• Solubility: DMSO:77 mg/mL (181.85 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.72 mM)

Bioactivity

• In Vivo:
  Compare with MCC950, CY-09 treatment in vivo efficiently suppresses monosodium urate (MSU) injection-induced IL-1β production and neutrophil influx, suggesting that CY-09 can block MSU-induced NLRP3 inflammasome activation in vivo. CY-09 treatment also increases the survival of NLRP3mutant mice up to days 30 to 48 even after treatment is stopped at day 25. The caspase-1 cleavage observed in adipose tissue of HFD-treated mice is also suppressed by CY-09
• In Vitro:
  CY-09 demonstrates a dose-dependent decrease in monosodium urate (MSU), nigericin, and ATP-triggered caspase-1 activity and IL-1β release across 1 to 10 μM concentrations in LPS-primed bone marrow-derived macrophages (BMDMs). It effectively prevents cytosolic LPS-induced noncanonical NLRP3 activation in BMDMs. Notably, CY-09, like MCC950, selectively curbs NLRP3 inflammasome activity without impacting LPS-induced priming effects. Additionally, CY-09 significantly hinders nigericin-induced ASC oligomerization and disrupts Flag-NLRP3 and mCherry-NLRP3 interactions in HEK-293T cells, indicating a blockage of NLRP3 oligomerization by CY-09.
• Cell Research:
  To induce NLRP3 inflammasome activation, 5×105/mL BMDMs and 6×106/mL PBMCs are plated in 12-well plates. The following morning, the medium is replaced, and cells are stimulated with 50 ng/mL LPS or 400 ng/mL Pam3CSK4 (for noncanonical inflammasome activation) for 3 h. After that, CY-09 or other inhibitors are added into the culture for another 30 min, and then the cells are stimulated for 4 h with monosodium urate (MSU) (150 μg/mL), Salmonella typhimurium (multiplicity of infection) or for 30 min with ATP (2.5 mM) or nigericin (10 μM). Cells are transfected with poly(dA:dT) (0.5 μg/mL) for 4 h or LPS (500 ng/mL) overnight. Cell extracts and precipitated supernatants are analyzed by immunoblot.
• Animal Research:
  For the in vivo experiments, CY-09 is formulated in a vehicle containing 10% DMSO, 10% Solutol HS 15, and 80% saline,WT or Nlrp3 / mice at the age of 6 wk, with similar plasma glucose levels and body weights are randomized into different groups. For generation of high-fat diet (HFD)-induced diabetic mice, mice are fed with HFD for 14 wk. The diabetic mice are treated with CY-09 (i.p.) at a dose of 2.5 mg/kg once a day for 6 wk. The mice are maintained with HFD when used for CY-09 treatment and the subsequent experiments.

Storage & Handling

• Storage: store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CY09, CY-09, CY 09, NOD-like Receptor, NODlikeReceptor, NODlikeReceptor(NLR), NOD-like Receptor (NLR), NODlike Receptor (NLR), NLRP3, NLR, inhibit, Inhibitor

Compound Identifiers

PubChem CID

75070350